retatrutide and type 1 diabetes mechanism triple agonist gip glp-1 glucagon Targeting GLP-1, & GCG in Obesity 2 Research Beyond GLP-1: Retatrutide's triple-agonist mechanism – 🩺 Retatrutide in type 2

Our physicians determine appropriate dosing based on your baseline IGF-1 and treatment goals, and monitor response through regular lab testing

Rakhat, Y., et al

They found significantly increased cord blood MDA levels in samples obtained during spray seasons and increased fetal DNA fragmentation, indicating enhanced fetal OS

My only hesitation in accepting the hypothesis that obesity is a downstream effect of hypothalamic inflammation lies in the fact that, in metabolically healthy individuals, a normally functioning digestive system, a non-steatotic liver, nutrient-sensitive pancreas and intestine, insulin-sensitive adipose tissue, should mitigate, at least to some extent (though not completely), the negative effects of an unhealthy diet, until their compensatory capacity fails